Early Access — free while we kick the tires
EdgarHawk

CAI Caris Life Sciences, Inc. Insider Trading

Latest: Director Bought $501K of Shares · May 2026
1 filing analyzed · Latest 2026-05-12
Insider buys
1
Insider sells
0
Unique insiders
1
Direction
Net buying
May 2026
2026-05-12
high
Vacirca Jeff L Buy
31,050 shares
$501,426
@ $16.15
Significance 6/10

Director Vacirca Jeff L purchases 31,050 shares at $16.15, doubling his stake while stock trades well below 52-week highs.

Director Jeff Vacirca is making his second open-market purchase in the past two years, this time acquiring a substantial block that nearly doubles his holdings. The purchase occurs while the stock trades significantly below its 52-week high, having declined notably over the past three months. Vacirca's prior purchase history shows strong subsequent returns, with all prior buys resulting in gains within 90 days, suggesting he has demonstrated timing acuity on previous entries. However, the company remains unprofitable despite strong revenue growth, creating a mixed backdrop: the business is expanding rapidly, but profitability remains elusive. For a director without officer-level operational responsibilities to commit this level of capital at a depressed price point is noteworthy, though the unprofitable fundamentals suggest he is buying into a turnaround story rather than capitalizing on an already-stable business.

More Health Services companies

Get alerts for CAI

Add CAI to your watchlist and we'll email you when an insider files a Form 4 — with our AI's significance score and a plain-English read of what it means.

Sign up — free during early access